Authors:
Address: Department of Medicine, Johns Hopkins University School of Medicine, 10755 Falls Road, Suite 200, Lutherville, MD, 21093, USA, jaucott2@jhmi.edu.
Journal:

Publication:

abstract

PURPOSE:

A subset of patients treated for Lyme disease report persistent or recurrent symptoms of unknown etiology named Post-treatment Lyme disease syndrome (PTLDS). This study aims to describe a cohort of participants with early, untreated Lyme disease, and characterize post-treatment symptomatology and functional impact of PTLDS over time.

METHODS:

Sixty-three participants with erythema migrans and systemic symptoms were enrolled in a prospective cohort study. Participants underwent physical exams and clinical assessments, and completed the SF-36 (daily life functioning) and the Beck Depression Inventory, Second Edition (BDI-II) (depression), at each of five visits over a period of 6 months.

RESULTS:

Signs of Lyme disease disappeared post-treatment; however, new-onset patient-reported symptoms increased or plateaued over time. At 6 months, 36% of patients reported new-onset fatigue, 20% widespread pain, and 45% neurocognitive difficulties. However, less than 10% reported greater than "minimal" depression across the entire period. Those with PTLDS (36%) did not differ significantly from those without with respect to demographics, pre-treatment SF-36, and BDI-II scores. Statistically significant differences were found over time on the Role Physical, Vitality, Social Functioning, Role Emotional, and Mental Health subscales (with a trend toward significance for the remaining three subscales of Physical Functioning, Bodily Pain, and General Health) of the SF-36 between those with an eventual PTLDS diagnosis and those without when measured at 6 months.

CONCLUSIONS:

Unlike clinical signs of Lyme disease, new-onset symptoms are reported by a subset of participants without evidence of depressive symptomatology. Patients who developed PTLDS had significantly lower life functioning compared to those without PTLDS. We propose future avenues for researching infection-triggered symptoms resulting from multiple mechanisms.

Related Articles
Final Report on Carcinogens Background Document for Styrene.
Rep Carcinog Backgr Doc. 2008
Final Report on Carcinogens Background Document for Styrene.
National Toxicology Program. Rep Carcinog Backgr Doc. 2008 Sep; (8-5978):i-398.
Functional status in patients with chronic fatigue syndrome, other fatiguing illnesses, and healthy individuals.
Am J Med. 1996
Functional status in patients with chronic fatigue syndrome, other fatiguing illnesses, and healthy individuals.
Buchwald D, Pearlman T, Umali J, Schmaling K, Katon W. Am J Med. 1996 Oct; 101(4):364-70.
Clinical significance of lifetime mood and panic-agoraphobic spectrum symptoms on quality of life of patients with rheumatoid arthritis.
Compr Psychiatry. 2006
Clinical significance of lifetime mood and panic-agoraphobic spectrum symptoms on quality of life of patients with rheumatoid arthritis.
Piccinni A, Maser JD, Bazzichi L, Rucci P, Vivarelli L, Del Debbio A, Catena M, Bombardieri S, Dell'Osso L. Compr Psychiatry. 2006 May-Jun; 47(3):201-8.
Review Psychological treatment for insomnia in the regulation of long-term hypnotic drug use.
Health Technol Assess. 2004
Review Psychological treatment for insomnia in the regulation of long-term hypnotic drug use.
Morgan K, Dixon S, Mathers N, Thompson J, Tomeny M. Health Technol Assess. 2004 Feb; 8(8):iii-iv, 1-68.
Review Social functioning: should it become an endpoint in trials of antidepressants?
CNS Drugs. 2005
Review Social functioning: should it become an endpoint in trials of antidepressants?
Bech P. CNS Drugs. 2005; 19(4):313-24.

To top • Home

---

Show map | Diseases | Vaccination | Chronic disease | Medicine | Pregnancy | Heat & Sunburn | Cold | Security | Useful tips | Faq | News

TraveldoctorOnline 2001 • Disclaimer • webmaster